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IRF3-dependent innate response in
dendritic cells.
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Dendritic cells (DCs) play a critical role in the immune
response to viral infection through the facilitation of
cell-intrinsic antiviral activity and the activation of
adaptive immunity. HIV-1 infection of DCs triggers
an IRF3-dependent innate immune response, which
requires the activity of cyclic GAMP synthase
(cGAS). We report the results of a targeted RNAi
screen utilizing primary human monocyte-derived
DCs (MDDCs) to identify immune regulators that
directly interface with HIV-1-encoded features to
initiate this innate response. Polyglutamine binding
protein 1 (PQBP1) emerged as a strong candidate
through this analysis. We found that PQBP1 directly
binds to reverse-transcribed HIV-1 DNA and inter-
acts with cGAS to initiate an IRF3-dependent
innate response. MDDCs derived from Renpenning
syndrome patients, who harbor mutations in the
PQBP1 locus, possess a severely attenuated innate
immune response to HIV-1 challenge, underscoring
the role of PQBP1 as a proximal innate sensor of a
HIV-1 infection.
INTRODUCTION
Innate immune responses that trigger type-I interferon (IFN)
secretion have been implicated in HIV-1 transmission and path-
ogenesis (Gringhuis et al., 2010; Iwasaki, 2012; Meier et al.,
2009). HIV-1 has evolved countermeasures to escape the activ-
ities of several IFN-stimulated genes (ISGs), and those mecha-
nisms not disabled by the virus define both cell type and species
tropisms (Kirchhoff, 2010). Recent data suggest that one ormoreintrinsic signaling pathways sense invariant features encoded by
HIV-1 and initiate innate immune responses, including IFN secre-
tion (Gao et al., 2013; Jakobsen et al., 2013; Manel et al., 2010;
Rasaiyaah et al., 2013). This response is proximally mediated
by recognition of specific viral components in infected cells by
pattern recognition receptors (PRRs), resulting in the activation
of transcription factors that participate in ISG expression and
IFN synthesis, such as IRF3 (Luban, 2012; Paludan and Bowie,
2013). Dendritic cells (DCs) play a critical role in immune
response to viral infection through the facilitation of cell-intrinsic
antiviral activity and the activation of adaptive immunity. Human
DCs are resistant to HIV-1 infection because of expression of
SAMHD1, a phosphohydrolase that functions to deplete cellular
nucleotide pools (Berger et al., 2011; Goldstone et al., 2011;
Lahouassa et al., 2012). SAMHD1 restriction can be overcome
in DCs by the introduction of HIV-2- or SIV-encoded Vpx, both
of which target SAMHD1 for ubiquitin-mediated degradation
(Hrecka et al., 2011; Laguette et al., 2011, 2012). Manel et al.
(2010) have demonstrated that co-transduction of DCs with
HIV-1 and SIV VLP-Vpx not only enables productive infection
but also results in the activation of DCs and IRF3-dependent pro-
duction of IFN.
Furthermore, studies have shown that this IRF3-dependent
innate immune response requires the activity of cyclic GAMP
synthase (cGAS) (Gao et al., 2013; Sun et al., 2013; Wu et al.,
2013). cGAS has been identified as a critical mediator of the
innate response to cytosolic DNA through synthesis of a cyclic
guanosine monophosphate–adenosine monophosphate isomer
(cGAMP) (Sun et al., 2013). While cGAS was shown to regulate
anti-viral responses to HIV-1 and other retroviruses, its direct
association with a retroviral-encoded PAMP has not been
demonstrated (Gao et al., 2013; Li et al., 2013). Additionally,
the apparent low affinity of cGAS for DNA and the promiscuous
response to a broad set of DNA ligands suggests that co-recep-
tors may function to enhance affinity for non-self DNA duringCell 161, 1293–1305, June 4, 2015 ª2015 Elsevier Inc. 1293
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Figure 1. A Targeted RNAi Screen to Identify Innate Immune Sensors of HIV-1 Infection
(A) MDDCs were infected with HIV/Vpx-encoding luciferase for the indicated duration (left). ISG54mRNA levels were measured after infection in the absence or
presence of antiviral drugs NVP (5 mM) or Ral (5 mM) (middle). Viral infectivity was evaluated by assessing viral luciferase activity (right).
(B) MDDCs treated as in (A) were assayed for p-IRF3 and p-IKKε levels by western blot.
(C) MDDCs were transfected with siRNAs targeting IRF3 and NF-kB (p65), and relative ISG54 induction wasmeasured 12 hr post-infection. ‘‘None’’ indicates that
the cells were not transfected.
(D) A schematic depicting the screening process (left). The average and SD of ISG54mRNA levels in MDDCs depleted of each putative co-sensor is shown (right).
The scramble control activities are depicted in the large red circles. The horizontal dotted line reflects the three SD cutoff from the controls. The p value was
determined by one-tailed, unpaired t test (p% 0.0001). This screen was run in biological duplicates.
Except in (D), all data are shown as the average ±SD of biological triplicates. *p < 0.05 as determined by one-way ANOVAwith Tukey’s post-test. (A)–(C) represent
data from at least three independent experiments. See also Figure S1 and Table S1 for additional validation studies of the screening platform.cGAS-dependent innate signaling (Kranzusch and Vance, 2013).
Results from this study indicate that the polyglutamine binding
protein 1 (PQBP1) protein functions as a specific co-receptor
for reverse-transcribed HIV-1 DNA and complexes with cGAS
to initiate an immune response to retroviral infection.
RESULTS
As previously observed, when monocyte-derived DCs (MDDCs)
were co-infected with SIV VLP-Vpx and vesicular stomatitis virus
G protein (VSV-G)-HIV-1 (hereafter HIV/Vpx), we detected robust
expression of IRF3-dependent target genes ISG54 and IP-10,
peaking at 16 hr post-infection (Figure 1A; Figure S1A). Infection
with either HIV-1 or Vpx alone did not result in an appreciable in-
crease of these transcripts (Figure 1A). Expression of ISG54 in
response to HIV/Vpx was accompanied by phosphorylation-
dependent activation of IRF3 and its upstream regulator, IKKε
(Figure 1B). In addition, ISG54 induction by HIV/Vpx was IRF31294 Cell 161, 1293–1305, June 4, 2015 ª2015 Elsevier Inc.dependent, as demonstrated by IRF3 silencing; depletion of
IRF3, but not p65, attenuated early induction of ISG54 (Figures
1C and S1B). Consistent with a previous report (Gao et al.,
2013), we found that this signaling response required reverse
transcription (RT) of HIV-1 RNA, but not viral DNA integration
treatment with Nevirapine (NVP), an RT inhibitor, reduced
ISG54 expression and phosphorylation of IRF3, but treatment
with the integrase inhibitor Raltegravir (Ral) did not (Figures 1A
and 1B). Both treatments were effective as they potently in-
hibited viral replication, but they did not affect cell viability or
innate responses to non-HIV-1 stimuli (Figure 1A, right; Fig-
ure S1C). These data confirm that HIV-1 elicits an IRF3-depen-
dent innate immune response in MDDCs through a process
that requires viral reverse transcription.
To identify potential co-sensors that regulate this response,
we performed a targeted RNAi screen in primary MDDCs.
Because our data suggest that a viral DNA-containing species
is likely responsible for the initiation of signaling, we reasoned
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Figure 2. PQBP1 Regulates the Innate Immune Response to HIV-1 in Primary Human DCs and Human Monocytic Cell Lines
(A) ISG54 expression was measured in MDDCs transfected with four independent siRNAs targeting PQBP1 and challenged with HIV/Vpx for 8 hr (left).
A scrambled siRNA and a siRNA targeting an unrelated innate regulator (LRRFIP1) were utilized as negative controls, and a siRNA targeting IRF3 was employed
as a positive control. Expression of each gene was calculated relative to mRNA levels after transfection with the scramble siRNA (right) (* represents a significant
[p < 0.05] difference from the scramble).
(B) THP-1 cells were transfected with siRNAs targeting the indicated genes and a scramble control for 48 hr, followed by HIV/Vpx infection; the indicated protein
levels were then analyzed.
(C) V5-tagged WT-PQBP1-THP-1 (expressing wild-type PQBP1) or siR-PQBP1-THP-1 (expressing siRNA-resistant PQBP1) cells were transfected with either a
control or PQBP1-targeting siRNA and infected with HIV/Vpx for 8 hr. Then the fold induction of ISG54 in comparison to uninfected sample was measured
(top panel). V5-tagged PQBP1 protein expression is shown (bottom panel).
(D) CRISPR-generated PQBP1 THP-1 cells were PMA-differentiated and infected with HIV/Vpx or stimulated with HT-DNA for 8 hr, and then ISG54 induction was
measured (top). Loss of PQBP1 protein in cPQBP1 cells was confirmed by western blot (bottom).
(E) cPQBP1 clones were stably reconstituted with V5-tagged wild-type PQBP1 and infected with HIV/Vpx, and the ISG54 fold induction was compared in all
lines (top). Expression of V5-PQBP1 protein in the rescue lines is shown (bottom).
(A) and (B) represent data from at least three independent experiments. (C)–(E) are a representative of two independent experiments, and the data are shown as
the mean ± SD of biological triplicates. See also Figure S2.that putative receptors would possess annotated nucleic acid
binding activity and be preferentially expressed in myeloid cells.
Based on these criteria, we assembled a sub-genomic RNAi
library of 351 putative sensors (see Experimental Procedures;
Table S1). Each candidate gene was individually depleted by
transfecting a pool of four small interfering RNAs (siRNAs) per
gene into MDDCs. After 48 hr, the cells were challenged with
HIV/Vpx, and induction of innate signaling was measured by
monitoring ISG54 expression (Figure 1D; Table S1).We identified26 genes that when depleted inhibited ISG54 mRNA induction
greater than three SD below the scrambled controls (Figure 1D;
Table S1, p% 0.0001).
To further validate these results, four siRNAs for each putative
sensor were tested independently. One of the strongest candi-
dates that reproducibly and potently inhibited ISG54 induction
with at least two sequence-independent siRNAs targeted the
gene PQBP1 (Figure 2A; Figures S2A–S2C; Table S1). PQBP1
is a polyglutamine-binding protein, and mutations in theCell 161, 1293–1305, June 4, 2015 ª2015 Elsevier Inc. 1295
010
20
30
40
50
A
 R
el
. a
bu
nd
an
ce
 
Post HIV-1 infection
3hrs 16 hrs
N. IgG-IP
ZC3H3-IP
PQBP1-IP
 R
el
. a
bu
nd
an
ce
 
PQBP1 IP
RNase A/HDNase
qPCR
RT
RNA DNA
qPCR
B
RNA DNA
N. IgG
PQBP1
Fo
ld
 e
nr
ic
hm
en
t o
f H
IV
-1
 D
N
A
NV
P Ra
l-
C
0
2
4
6
8
shControl
shPQBP1
0
100
200
300
400
500
600
200 200 50 170-
plas lin SNC C
(ng)
D
shPQBP1
0
1
2
3
4
5
shControl
no
ne
 
PQ
BP
1-I
P
N.
IgG
-IP
G H
PQ
BP
1-I
P
N.
IgG
-IP
pla
sm
id
0
1
2
3
4
5
6
7
50 10 10-(ng) 10 10
NVP: - - + +- -
PQ
BP
1-I
P
N.
IgG
-IP
In
pu
t
PQBP1
N. 
IgG
ZC3H3
IP
ZC
3H
3
PQ
BP
1
LTR LTR
eRT +7000
HIV-1
3’LTR
-37kda
-100kda
0
4
8
12
16
20
sh
luc
sh
cG
AS
Fo
ld
 e
nr
ic
hm
en
t H
IV
-1
 D
N
A
shluc shcGAS
inp
ut
N.
Ig
G
α-P
QB
P1
inp
ut
N.
Ig
G
α-P
QB
P1
PQBP1
PMA-THP
F
E
0.0
0.4
0.8
1.2
 R
el
. P
Q
BP
1 
m
RN
A
sh
Co
ntr
ol
sh
PQ
BP
1
β-actin
sh
C
on
tro
l
PQBP1
sh
P
Q
B
P
1
-37kda
-50kda
-actin
sh
lu
cl
  cGAS
sh
cG
A
S
-100kda
-50kda
Figure 3. PQBP1 Associates with Immunogenic HIV-1 DNA
(A) MDDCswere challenged with HIV/Vpx for 3 or 16 hr, followed by formaldehyde cross-linking. The abundance of HIV-1-encoded nucleic acids associating with
the PQBP1 IP or the ZC3H3 IP was evaluated using qRT-PCR using primers for the HIV-1 strong stop sequence (left) (eRT primers; Table S2). The values are
relative to the level of nucleic acids that precipitated by normal IgG from the 3-hr-infected lysate. Binding specificity of the antibodies was confirmed by western
blot of the immunoprecipitants (right). The schematic depicts the HIV-1 genome with the three sets of primers used to measure the amount of HIV-1 nucleic acid.
See also Figure S3C.
(B) THP-1 cells that stably expressed shRNA-targeting luciferase or cGAS were infected with HIV/Vpx for 6 hr, formaldehyde cross-linked, lysed, and immu-
noprecipitated with a PQBP1 antibody. The fold enrichment of HIV-1 DNA (30LTR) pulled down by the PQBP1-IP over normal IgG-IP is indicated (top). A western
blot of cGAS protein in shcGAS cells compared to shLuc control (right) is provided. A western blot shows levels of PQBP1 protein immunoprecipitated from both
samples (bottom).
(C) Immunoprecipitants described in (A) were treated with either DNase or RNaseA/H, as shown in schematic, and HIV-1 nucleic acid levels (30LTR) were
measured as described.
(D) MDDCswere challenged with HIV/Vpx for 6 hr in the absence or presence of NVP (5 mM) or Ral (5 mM). Fold enhancement of HIV-1 sequences (30LTR) from the
PQBP1 IP over the control normal IgG IP measured by qPCR is indicated.
(legend continued on next page)
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PQBP1 locus are associated with neurodegenerative pathol-
ogies, including Renpenning and other syndromes associated
with X-linked mental disorders (XLMR; Germanaud et al., 2011;
Kalscheuer et al., 2003; Lenski et al., 2004; Marubuchi et al.,
2005). RNAi depletion of a putative nucleic acid sensor LRRFIP1,
a gene that did not meet the three SD threshold in the original
screen, did not reduce ISG54 induction when compared to the
scrambled controls (Figure 2A), and it was thus used as a nega-
tive control in subsequent experiments.
The PQBP1-dependent induction of innate immune signaling
after HIV-1 infection was not unique to MDDCs. Knockdown of
PQBP1 in the monocyte-like cell line THP-1 also resulted in
reduced ISG54 induction after HIV-1 infection (Figure S2D).
We investigated the possibility that PQBP1 was reducing ISG
induction through interference with HIV-1 replication. However,
HIV-1 infection was unimpeded in the absence of PQBP1, as
compared to cells harboring a control small hairpin RNA (shRNA)
(Figure S2E). Evaluation of IKKε and IRF3 phosphorylation after
HIV/Vpx challenge in PMA-differentiated THP-1 cells (hereafter
THP-1) depleted of PQBP1 indicated that PQBP1 acts as a pos-
itive regulator of ISG54 and IP-10 induction upstream of IKKε/
IRF3 phosphorylation (Figure 2B; Figure S2C). To exclude poten-
tial off-target siRNA effects, THP-1 lines that stably expressed
either wild-type PQBP1 or siRNA-resistant PQBP1 cDNAs
were generated, transfected with a siRNA targeting PQBP1,
and challenged with HIV/Vpx. Expression of the siRNA-resistant
PQBP1 (siR) restored ISG54 and IP10 expression in response to
infection (Figures 2C and S2F). However, those cells harboring
wild-type PQBP1 displayed attenuated induction of ISG54
(Figures 2C and S2F). Additionally, we employed a CRISPR-
mediated genome editing approach to target PQBP1 (cPQBP1;
Supplemental Experimental Procedures). We were unable to
generate lines harboring genetically null mutations for PQBP1,
but we were successful in recovering several hypomorphic mu-
tations in the PQBP1 locus that resulted in significantly dimin-
ished levels of PQBP1 expression. Similar to transient silencing
of PQBP1 in DCs or THP-1 cells, we found genome editing of
PQBP1 in THP-1 cells abrogated ISG54 induction after HIV/
Vpx infection, but not after HT-DNA stimulation (Figure 2D).
ISG54 induction was rescued after adding a stable, ectopically
expressed PQBP1 (Figure 2E).
We subsequently sought to determine if PQBP1 directly asso-
ciatedwith HIV-1-encoded PAMPs. To this end,MDDCswere in-
fected with HIV/Vpx for 3 or 16 hr, formaldehyde cross-linked,
lysed, and subjected to immunoprecipitations (IP) of endoge-
nous PQBP1 or ZC3H3, another nucleic acid binding protein
that was identified in our screen (Table S1). Specific pull down(E) Knockdown efficiency of PQBP1 in THP-1 cells expressing shRNAs against a
western blot (right).
(F) Infected MDDC lysates were separated into soluble non-chromatin (SNC) a
encoding HIV-1 proviral DNA (circular or linearized), were electroporated into TH
expression was measured.
(G) The co-immunoprecipitated DNA as in (A) was eluted and electroporated into
was assessed.
(H) MDDCs in the absence or presence of NVP were infected with HIV/Vpx for 6 hr
PMA-THP, and ISG54 expression was assessed.
Data in (A)–(D) are shown as the average ± SD of technical quadruplicates. (A)–(D
representative of two independent experiments. *p < 0.05 as determined by oneof PQBP1 or ZC3H3 proteins was confirmed by western blot
(Figure 3A, right), and HIV-1-derived nucleic acids associating
with the normal serum, ZC3H3, and PQBP1 IPs were quantitated
by qRT-PCR. We found that a significant and specific enrich-
ment of HIV-1-derived nucleic acids was associated with the
PQBP1 IP, but not with the ZC3H3 or control IP (normal immuno-
globulin G [IgG]) (Figure 3A; Figures S3A and S3B). To further
confirm the selectivity of binding, a recombinant glutathione
S-transferase (GST)-tagged PQBP1 protein was added during
the IP to displace endogenous PQBP1. Addition of exogenous
PQBP1 reduced the level of HIV-1 nucleic acids in the immuno-
precipitants (S3C). To understand whether PQBP1 association
with HIV-1 DNA required the innate regulator cGAS, cells that
stably expressed an shRNA vector targeting either luciferase or
cGAS were infected for 6 hr. They were then cross-linked, and
PQBP1 was immunoprecipitated from the lysate, as described
above. Despite the absence of cGAS, PQBP1 was still able to
associate with HIV-1 nucleic acids (Figure 3B). Next, to identify
the species of HIV-1-encoded nucleic acid that was involved in
this activity, the IPs were treated with either DNase or RNase
A/H prior to qRT-PCR or qPCR analysis, respectively (Figure 3C).
HIV-1 nucleic acid products were detected only in the samples
treated with RNase A/H (Figure 3C). Additionally, PQBP1 binding
to the HIV-1 nucleic acids was significantly reduced in the
presence of the RT inhibitor NVP but was not affected by the
integrase inhibitor Ral (Figure 3D). These data suggest that an
HIV-1 DNA intermediate product associates with PQBP1.
To characterize the activity of HIV-1 DNA in the cytosol of
infected cells, MDDCs were infected with HIV/Vpx for 6 hr and
then fractionated into soluble non-chromatin (SNC) and chro-
matin (C) fractions (Figure S3F). At this time point after infection,
we found that HIV-1-encoded nucleic acids exist primarily in
the SNC (Figure S3F). Consistently, electroporation of RNase-
A/H-resistant nucleic acids isolated from either the SNC or
C fractions of HIV-1-infected MDDCs into naive THP-1 cells
harboring a stable shRNA toward PQBP1 (Figure 3E) revealed
that DNA, or possibly an RNaseH-resistant RNA-DNA hybrid
species, present in the soluble fraction of infected cells is immu-
nogenic, and the immune response to this ligand is dependent
upon PQBP1 expression in uninfected target cells (Figure 3F).
We then tested whether the PQBP1-associated HIV-1 DNA
product was itself immunogenic. DNA immunoprecipitated
from the infected MDDC lysate by the PQBP1 antibody or the
control normal IgG was electroporated into THP-1 in the pres-
ence or absence of PQBP1. We found that only PQBP1-associ-
ated nucleic acids led to the enhancement of ISG54 expression
and that this innate response was sharply attenuated in thescramble control or the PQBP1 protein was measured by qRT-PCR (left) and
nd chromatin (C) fractions. DNA isolated from each fraction, and a plasmid
P-1 cells harboring a shRNA control or shRNA-targeting PQBP1, and ISG54
PMA-differentiated shControl or shPQBP1 THP-1 cells, and ISG54 expression
and treated as in (A), and the immunoprecipitated DNAwas electroporated into
) are representative of at least three independent experiments, and (F)–(H) are
-way ANOVA with Tukey’s post-test. See also Figure S3.
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Figure 4. PQBP1 Is a Specific Sensor of Retroviral DNA
(A) MDDCs were transfected with a control siRNA or siPQBP1 and challenged with HIV/Vpx, B-DNA, or HT-DNA, and then ISG54 expression was measured.
(B) PMA-differentiated shControl or shPQBP1 THP-1 cells were infected with HIV/Vpx or transfected with HT-DNA for 8 hr, followed by measuring ISG54 in-
duction. Both infection and transfection were performed in parallel.
(C) PMA-differentiated shControl or shPQBP1 THP-1 cells were infected with MHV-68 virus at an MOI 5, and ISG54 induction was measured.
(D) THP-1 cells were challenged with HIV/Vpx or MHV-68 for 6 hr, followed by formaldehyde cross-linking. The abundance of HIV-1- or MHV-68-encoded nucleic
acids or mDNAs associated with the PQBP1 IP was evaluated (Table S2).
(E) PMA-differentiated shControl or shPQBP1 THP-1 cells were infected with VSV-G pseudotyped FIV or EIAV, followed by measuring ISG54 induction.
(F) CRISPR PQBP1 clones were infected with increasing MOIs of FIV (left) or MHV-68 (right), and ISG54 induction was measured.
All data except (D) are shown as the average ± SD of biological triplicates and are representative of at least three independent experiments. For the THP-1
infectedwithMHV-68 in (D), the lysates were pooled from six biological replicates. Significance (*p < 0.05) was determined by one-way ANOVAwith Tukey’s post-
test (A and B) or by an unpaired Student’s t test (E). See also Figure S4.absence of PQBP1 in the target cells (Figure 3G). This innate in-
duction was specific to a reverse-transcribed DNA product,
since the PQBP1-IP product from cells treated with NVP during
infection failed to induce ISG54 expression in target cells (Fig-
ure 3H). Taken together, these results suggest that PQBP1
directly associates with immunogenic HIV-1 DNA.
Next, we evaluated the breadth of nucleic acid stimuli that are
governed by a PQBP1-dependent innate response. In contrast
to HIV-1, the innate immune response to an RNA virus, Sendai
virus, was not dependent upon PQBP1 in THP-1 (S4A). Further,
the dependence on PQBP1 for HIV-1 DNA recognition did not
extend to all cytoplasmic DNA, as response to B-DNA
(poly(dA:dT)) and Herring testis (HT)-DNA was not reliant on
PQBP1 in MDDCs or THP-1 cells (Figures 4A and 4B; Figures
S4B and S4C). Consistent with these results, PQBP1 depletion
did not dampen the immune response to the double-stranded
DNA virus MHV-68 (Figure 4C), and MHV-68 DNA did not asso-
ciate with PQBP1 after infection, despite a greater abundance of
MHV-68 in the lysate (Figures 4D and S4D). Feline immunodefi-
ciency virus (FIV) and equine infectious anemia virus (EIAV) are1298 Cell 161, 1293–1305, June 4, 2015 ª2015 Elsevier Inc.both retroviruses that are divergent from HIV-1 but maintain
the requirement of a reverse-transcription step for viral propaga-
tion. Both VSV-G-pseudotyped retroviruses induced an innate
response in THP-1. However, in the absence of the PQBP1
protein, the response was sharply reduced (Figures 4E and 4F;
Figure S4E). Taken together, these data indicate that PQBP1
specifically recognizes a retroviral DNA product.
Similar to previous reports (Gao et al., 2013), we found that
depletion of cGAS inMDDCs resulted in decreased ISG54 induc-
tion by both HT-DNA and HIV-1 (Figure 5A; Figure S5A). Since
PQBP1 is dispensable for the innate response to HT-DNA and
MHV-68 (Figures 4A–4C), both of which have been reported to
be sensed by cGAS (Schoggins et al., 2014; Sun et al., 2013),
our data suggest that PQBP1 regulates the response to a more
restricted set of cGAS-dependent DNA ligands. However,
because both PQBP1 and cGAS were required for response to
a RT DNA PAMP produced by HIV-1 infection (Gao et al.,
2013), we sought to determine whether PQBP1 and cGAS
modulate the response to HIV-1 through coincident or parallel
pathways. We evaluated whether PQBP1-depleted cells could
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Figure 5. PQBP1 Functions Upstream of cGAS and Regulates cGAS-STING-Dependent IRF3 Activation upon Retroviral Infection
(A)MDDCswere transfectedwith siRNAs targeting cGAS or a scramble control, challengedwith either HIV/Vpx or HT-DNA for 8 hr, and assayed for relative ISG54
mRNA levels.
(B) Synthetic cGAMP was incubated with PFO-treated shControl or shPQBP1 THP-1 cells, and induction of p-IRF3 was analyzed.
(C) Synthetic cGAMP was incubated with PFO-treated shcGAS, shSTING, and shLuciferase THP-1 cells, and induction of p-IRF3 was analyzed. Knockdown
efficiency of the target proteins in shcGAS and shSTING lines compared to the shLuc line is shown (right).
(D and E) cGAMP levels in the lysates of MDDCs transfected with indicated siRNAs (top) or PMA-differentiated shRNA THP-1 cells (bottom) were assayed prior to
and after HIV/Vpx infection. Infected cellular lysates were incubated with PFO-treated THP-1 cells, followed by western blot analysis to detect p-IRF3 (D) or
directly quantified using LC-MS/MS (E). The level of cGAMP was graphed as a percent increase in HIV-1-infected cells over the untreated samples either in the
presence (si/shControl) or absence of PQBP1 protein (si/shPQBP1).
(F) cGAMP levels in the lysates of MDDCs were assayed prior to and after HT-DNA stimulation. cGAMP was directly quantified using LC-MS/MS. The level of
cGAMPwas graphed as a percent increase in HT-DNA-stimulated cells over the untreated samples either in the presence (siControl) or absence of cGAS protein
(sicGAS). Knockdown efficiency of cGAS protein in the lysate is shown at the bottom.
(A) is shown as the average ± SD of biological triplicates. The data in (A)–(E) are representative of at least two independent experiments. In (D)–(F) the data were
from six biological replicates pooled to generate the lysate. For the MDDCs, a single donor was used for the biological replicates in a single experiment. The data
are representative of four independent experiments. For the experiments using THP-1, two independent experiments were performed. Significance (*p < 0.05)
was determined by an unpaired Student’s t test. See also Figure S5.respond to exogenously added synthetic cGAMP.When cGAMP
molecules were incubated with perfringolysin O (PFO)-treated
THP-1 cells harboring PQBP1 shRNA, as previously described
(Wu et al., 2013), we did not observe a reduction of cGAMP-
induced p-IRF3 in comparison to control cells (Figure 5B), but
there was a reduction of cGAMP-mediated activation in the
absence of STING (Figure 5C). This result suggested that
PQBP1 activity is not required for cGAMP-mediated activation
of IRF3. Next, we evaluated the impact of PQBP1 depletion onthe synthesis of cGAMP after HIV-1 challenge. Both qRT-PCR
analysis and western blot analysis confirmed that depletion of
PQBP1 does not reduce cGAS expression (Figure S5B). MDDCs
or THP-1 were transfected with siPQBP1 and infected with HIV/
Vpx. cGAMP levels in the infected cell lysates were indirectly
measured through incubation of PFO-treated THP-1 cells with
those lysates, and phosphorylation of IRF3 was assessed
(Figure 5D). cGAMP levels were also directly quantified by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)Cell 161, 1293–1305, June 4, 2015 ª2015 Elsevier Inc. 1299
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Figure 6. The WW Domain of PQBP1 Directs Interaction with cGAS
(A) MDDCs (left) and THP-1 (right) were fractionated, as shown in the schematic (left), yielding a soluble cytosolic component (S1), a membrane- and organelle-
associated component (S2), and a chromatin component (P2). Presence of cGAS, STING, DDX3X, Histone-H3, and PQBP1 in specific fractions wasmeasured by
western blot.
(B) THP-1 cells stably expressing V5-tagged WT-PQBP1 were lysed and immunoprecipitated for V5 or a normal serum IgG and then probed for endogenous
cGAS.
(C) HEK293T cells were transfected with eYFP-tagged PQBP1 or eYFP, V5-tagged cGAS, and/or FLAG-tagged STING. The cells were lysed and eYFP was
immunoprecipitated, followed by a western blot for V5 or FLAG.
(D) HEK293T cell lysates expressing V5-tagged cGAS and eYFP-taggedwild-type (WT), C-terminal truncationmutant (delC), or WWdomainmutant (WW) PQBP1
were immunoprecipitated with an antibody against eYFP and probed for V5.
(A)–(D) are representative of at least two independent experiments.(Figures 5E and 5F; Figures S5C–S5E). In both MDDCs and
THP-1, the loss of PQBP1, even in the presence of functional
cGAS, resulted in a significant reduction of cGAMP production
upon HIV/Vpx infection (Figures 5D and 5E). As cGAS is the
only enzyme known to generate cGAMP in mammalian cells,
we conclude that PQBP1 is required for activation of cGAS
during HIV-1 infection of myeloid cells.
Consistent with other studies (Waragai et al., 1999; Kunde
et al., 2011), immunofluorescent staining of endogenous
PQBP1 revealed that it was localized to both the cytosol and
nucleus of MDDCs (Figure S3E). To determine if PQBP1,
cGAS, and STING are in similar cellular compartments during
HIV-1 infection, we performed a subcellular fractionation and
found that PQBP1 co-fractionates with cGAS and STING (Fig-
ure 6A). To determine if PQBP1 physically interacts with cGAS,
we performed an IP of THP-1 cells stably expressing V5-
PQBP1, immunoblotted for endogenous cGAS, and found that
PQBP1 physically associated with cGAS in the absence of1300 Cell 161, 1293–1305, June 4, 2015 ª2015 Elsevier Inc.immune stimulation (Figure 6B). Next, we expressed eYFP-
tagged PQBP1, V5-tagged cGAS, and FLAG-tagged STING in
HEK293T, which lack both endogenous cGAS and STING, and
immunoprecipitated PQBP1. As expected, cGAS co-immuno-
precipitated with PQBP1; in contrast, when PQBP1 and STING
were expressed together in the absence of cGAS, we observed
no interaction between the two proteins (Figure 6C). However,
when PQBP1, cGAS, and STING were expressed simulta-
neously, STING was able to associate with PQBP1, indicating
that PQBP1 is able to form a complex with STING bridged by
cGAS (Figure 6C). To determine the domain necessary for
PQBP1-cGAS interaction, two disease-associated mutations
were generated: a truncation mutation that shortens the protein
at the C terminus without disrupting the WW domain (delC) and
an amino-acid substitution that disrupts the WW domain (WW)
(Lenski et al., 2004) (Figure 6D). Immunoprecipitation experi-
ments revealed that PQBP1 required an intact WW domain
(WW), but not a complete C terminus (delC), for binding cGAS
(Figure 6D). The PQBP1WW domain has previously been shown
to be required for interactions with other proteins (Ikeuchi et al.,
2013; Salah et al., 2012).
Next, we sought to determine which domain(s) of PQBP1 were
necessary for DNA binding. To this end, we determined that
recombinant PQBP1 (rPQBP1) specifically associated with
HIV-1 DNA, as there was an enrichment of reverse-transcribed
HIV-1 DNA, but not a HIV-1-encoding plasmid associated with
rPQBP1 (Figure 7A). Then GST-tagged recombinant wild-type,
C-terminal truncation (GST1-176), or WW domain mutant
(GST-WW) proteins were generated, and each was incubated
with non-chromatin DNA from cells infected with HIV/Vpx. A
PQBP1 antibody was used to immunoprecipitate the recombi-
nant proteins, and the amount of bound HIV-1 DNA was as-
sessed using qPCR. Whereas wild-type and GST-WW bound
HIV-1 DNA, GST1-176 associated with significantly less DNA
(Figure 7B). Through fractionation, we determined that the WW
domain and C-terminal truncation mutations did not affect the
localization of PQBP1 (Figure 7C). We then confirmed these
in vitro binding results using an in vivo nucleic acid binding
assay. PQBP1-depleted cPQBP1 cells were stably reconstituted
with wild-type, delC-PQBP1, or WW-PQBP1, and then the cells
were infected with HIV/Vpx for 6 hr, formaldehyde cross-linked,
and immunoprecipitated for PQBP1. Consistent with the in vitro
studies, wild-type and WW-PQBP1 associated with HIV-1 DNA,
but delC-PQBP1 did not (Figure 7D). Evaluation of ISG induction
in these reconstituted cells following HIV/Vpx infection indicated
that both cGAS and DNA binding domains were necessary for an
immune response to viral challenge (Figure 7E).
Finally, we evaluated the innate response to HIV-1 infection in
MDDCs derived from two Renpenning syndrome patients. The
two male patients harbor a genetic mutation in the X-linked
PQBP1 locus that results in a C-terminal truncation of amino
acids 153–265 in the protein. MDDCs derived from the patients
and healthy donors were challenged with HIV/Vpx for 8 hr, after
which time ISG54 expression was measured (Figure 7F).
Although paired healthy and Renpenning patient cells were in-
fected to similar levels (Figure S6A), MDDCs from both Renpen-
ning patients displayed severely impaired induction of ISG54 in
comparison to infected healthy donors (Figure 7F).
DISCUSSION
In this study, we find that the host protein PQBP1 directly binds
to an HIV-1 DNA PAMP generated after early infection and
initiates innate signaling through cGAS. Our results also indicate
that the HIV-1-encoded PAMP is likely based on a unique and
discernable secondary structure, which is only generated during
reverse transcription in the infected cell. Specifically, while
PQBP1 binds reverse-transcribed HIV-1 DNA from infected
cells, it is unable to associate with a HIV-1-encoding plasmid
DNA, in vitro reverse-transcribed DNA (data not shown), or other
DNA viruses (Figure 7A).
Interestingly, we observed that PQBP1 is not required for
cGAS-dependent responses to all cytosolic DNAs but only those
derived from retroviral infection. These results suggest that
PQBP1 and cGAS form a pattern recognition receptor complex
that specifically recognizes and responds to retroviral PAMP(s).While cGAS may serve as a common catalytic module for a
variety of cytosolic DNA ligands, its specific association with
PQBP1 enables cGAS to sense HIV-1-encoded DNA ligands.
Further studies are required to understand how PQBP1 modu-
lates the activation of cGAS in response to HIV DNA.
The reported affinity of cGAS for DNA is poor (KD20 mM), and
recognition is promiscuous (Civril et al., 2013; Kranzusch et al.,
2013; Zhang et al., 2014), inconsistent with its ability to specif-
ically respond to small quantities of microbial PAMPs and/or
self-DAMPs. It is currently unclear if cGAS requires co-sensors
analogous to PQBP1 to detect non-retroviral cytoplasmic DNA,
including HT-DNA. However, based on our results, we propose
a model in which cGAS, by virtue of its association with specific
co-receptors, such as PQBP1, increases its ability to recognize
distinct molecular patterns encoded by pathogen-associated
DNA. Similarly, LGP2 has been proposed to enhance the sensing
ability of the cytoplasmic RNA sensor MDA5 (Bruns et al., 2014;
Satoh et al., 2010). Therefore, this model may apply to multiple
innate immune sensors.
The experimental models in this report have relied on the intro-
duction of Vpx, which alleviates the block of early reverse tran-
scription at the minus strand strong stop in highly restrictive
cells, such as DCs (Hrecka et al., 2011; Laguette et al., 2011).
Previous work has indicated that abortive HIV-1 infection results
in the exposure of reverse-transcribed HIV-1 DNA intermediates
to trigger cGAS-dependent IRF3 activation (Lahaye et al., 2013;
Rasaiyaah et al., 2013). We hypothesize that circumventing
SAMHD1 restriction by Vpx increases the concentration of
both productive and abortive (late) RT intermediate products
during infection of myeloid cells, with the latter propagating a
potent and detectable innate response in these cells. Although
HIV-1 infection in the absence of Vpx does not induce a signifi-
cant innate response in myeloid cells in vitro, immune induction
during mucosal and acute infection has been observed in hu-
mans and non-human primate models (Abel et al., 2005; Katsikis
et al., 2011). Based on these observations, we propose that rare
abortive infection events are sufficient to trigger an innate im-
mune response in vivo, which is likely amplified during the course
of natural infection. However, in the absence of Vpx, these oc-
currences cannot be robustly detected on a cell population level
using current ex vivo cell culture model systems.
Finally, we find that PQBP1 mutations associated with
Renpenning syndrome severely attenuate the innate immune
response to HIV-1 infection in patient-derived myeloid cells.
Remarkably, each disease-associated PQBP1mutation resulted
in a corresponding defect in the immune response to retrovi-
ruses. Although a potential link between the observed innate im-
mune defect and the neurological impairments in Renpenning
patients remains uncertain, these data suggest that there may
be common features in the signaling architecture of the innate
immune response and neural development.
In summary, our results present a molecular understanding of
how HIV-1 and other retroviruses are uniquely and specifically
recognized to trigger cell-autonomous antiviral responses.
Further studies are warranted to better understand the specific
molecular characteristics of the HIV-1 DNA intermediates that
enable recognition by the PQBP1/cGAS axis and to determine
how this recognition event contributes to an antiviral andCell 161, 1293–1305, June 4, 2015 ª2015 Elsevier Inc. 1301
010
20
30
40
50
0
40
80
120
160
200
C D
B
0
30
60
90
120
R
el
at
iv
e 
bi
nd
in
g 
(%
)  
WT WW GST1-176-
Commassie
Stain
(input)
GS
T
W
T
W
W
GS
T1
-1
76
GST-PQBP1
(IPs)
GST-PQBP1
*
A
0
2
4
6
0
2
4
6
8
Pla
sm
id
non
chr
om
.
DN
A
R
el
at
iv
e 
H
IV
-1
 D
N
A 
   
R
el
. %
 in
pu
t b
in
di
ng
 (H
IV
-1
 D
N
A)
   
  
Pla
sm
id
GST
GST-PQBP1
non
chr
om
.
DN
A
Input
cGAS
STING
RIG-I
V5-PQBP1
S1 S2 P2
Histone-H3
S1 S2 P2 S1 S2 P2
WT WW delC
PMA-THP E
Fo
ld
 e
nr
ic
hm
en
t H
IV
-1
 D
N
A
WT WW WT delC
WT del.C
inp
ut
N.
Ig
G
α-
PQ
BP
1
inp
ut
N.
Ig
G
α-
PQ
BP
1
V5-PQBP1
WW
V5-PQBP1
WT
0
5
10
15
20
25
0
4
8
12
16
-WT
IS
G
54
 fo
ld
 in
du
ct
io
n 
 
WW delC
W
T
W
W
de
lCV5-PQBP1:
α-V5
-
cPQBP1
0
2
4
6
8
10
12
14
*
---
-
IS
G5
4 /
TB
P 
mR
NA
HIV-1
VPX 1/2X 1X1/2X1X
Normal-1
c.459_462delAGAG-1
Normal-2
c.459_462delAGAG-2
F
IS
G5
4 /
TB
P 
mR
NA
---
-
HIV-1
VPX 1/2X 1X1/2X1X
Figure 7. The C-Terminal Domain of PQBP1 Binds HIV-1 DNA and Is Required for the Innate Immune Response to HIV-1 Infection
(A) Recombinant GST or GST-tagged PQBP1 proteins were incubated with either an HIV-1 proviral plasmid or extra-chromosomal nucleic acids (non-chromatin
DNA) derived from HIV/Vpx-infected MDDCs andwere then immunoprecipitated by GST antibody. The relative abundance of HIV-1 DNA in the input (left) and the
IPs (right) is indicated, as measured by qPCR against HIV-1 30 LTR sequences.
(B) Recombinant GST or GST-PQBP1 proteins (WT, WW mutant, or C-terminal truncation [1–176] mutant) were incubated with non-chromatin DNA, as in (A),
followed by immunoprecipitation with a PQBP1 antibody. The graph at left depicts the relative binding of HIV-1 DNA to themutant proteins compared to the wild-
type PQBP1 protein. The blots at right show input and IP’edGST and/or GST-PQBP1 proteins used in the assay. – indicates GST-PQBP1 proteins, both wild-type
and mutants. * indicates a non-specific band.
(C) cPQBP1 THP-1 cells reconstituted with V5-tagged wild-type (WT), WW, or delC PQBP1 were fractionated as in Figure 6A, and the subcellular fractions were
analyzed for the indicated proteins.
(D) cPQBP1 THP-1 cells, stably reconstituted with wild-type (WT), delC, or WW mutant PQBP1, were infected with HIV/Vpx for 6 hr and were subjected to
formaldehyde cross-linking, followed by assaying for fold enrichment of HIV-1 DNA immunoprecipitated with the reconstituted PQBP1 protein over normal IgG
control. Levels of PQBP1 protein immunoprecipitated are shown by western blot (bottom).
(legend continued on next page)
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adaptive immune response to HIV-1. The identification of PQBP1
as an immune regulator required for sensing of retroviral DNA
provides an opportunity for the therapeutic development of
pharmacological agonists that may improve the efficacies of
HIV vaccines and prophylactics.
EXPERIMENTAL PROCEDURES
Cell Culture and Viral Infection
This studywas approved by the NIH through our Institute Biosafety Committee
(IBC). Primary monocyte-derived dendritic cells (MDDCs) were subjected to
siRNA transfection, and 2 days later they were infected with VSV-G pseudo-
typed HIV-1 virus harboring a firefly luciferase reporter and VLP-Vpx, as previ-
ously described (Manel et al., 2010). Six to 16 hr post-infection, RNA was
isolated from the cells and subjected to qRT-PCR analysis. For the viral repli-
cation assay, the infected MDDCs were harvested 48 to 72 hr post-infection
and assayed for luciferase activity from the integrated provirus. For mutation
analysis, peripheral blood mononuclear cells from both healthy donors and
two male Renpenning patients (mutation c.459_462 delAGAG, resulting in
type p.R153fs193X) were analyzed similar to above at the Paul-Ehrlich-Institut.
Biological replicates within each experiment represent independent infection
and/or treatments. Technical replicates represent qPCR replicates on each
biological sample. Replicate experiments were performed with MDDCs
derived from different donors. The human monocyte-like THP-1 cell line was
differentiated by treating with 5 ng/ml PMA (phorbol myristate acetate)
for 2 days, followed by siRNA transfection and viral infection as described
for MDDCs.
Virus Production and Infection
Preparation of VSV-G-pseudotyped HIV-1 firefly luciferase (luc), FIV, and EIAV
is described in the Supplemental Experimental Procedures. In general, 2.5 to
5 ng of p24 of HIV-1 virus or 104–105 IU (infectious units) of FIV or EIAV were
used per 25,000 PMA-THP. MHV-68 was a gift from Ren Sun at UCLA and
used at MOI of five. VLP-Vpx was generated using the SIV3+ plasmid as
previously described (Manel et al., 2010). The Mount Sinai Department of
Microbiology Virus Collection provided the Cantell strain of Sendai virus.
siRNAs and qRT-PCR
siRNAs were introduced into either MDDCs or PMA-THP using Stemfect RNA
transfection kits. Typically, 2.5–5 pmol of siRNAs and 0.14–0.18 ml of Stemfect
were used for 2.53 104 cells. Forty-eight hours after siRNA transfection, cells
were infected with indicated virus for 5 to 8 hr, followed by RNA isolation and
qRT-PCR analysis. The siRNA that knocked down PQBP1 most consistently
was used for all subsequent experiments. A list of the siRNAs and the qPCR
primers that were used in these experiments is shown in Table S2.
In Vivo Interaction Assay
Lysates prepared from MDDCs infected with HIV/Vpx for 6 hr (unless other-
wise indicated), followed by formaldehyde cross-linking (see the Supplemental
Experimental Procedures for detail), were subjected to immunoprecipitation
with 3–5 mg of antibody. The co-precipitated nucleic acids were analyzed by
either qRT-PCR or qPCR analysis. Unless indicated otherwise, the samples
that were analyzed by qPCR only were treated with RNaseA/H digestion prior
to proteinase K treatment.
For the fractionation experiments, the cross-linked MDDCs were lysed in a
Triton cell lysis buffer and the cleared supernatants (SNC) were separated from
the pellets, which were resuspended in equal volumes of Triton cell lysis buffer(E) cPQBP1 THP-1 cells, stably reconstituted with wild-type (WT), delC, or WW m
uninfected sample was measured by qRT-PCR. All panels are representative of
(F) MDDCs from two healthy donors and two male Renpenning syndrome patie
evaluated by qRT-PCR and normalized to TBP mRNA levels. ISG54 values for ea
determined using two-way ANOVA comparing HIV-1 challenged samples of hea
See also Figure S6.supplemented with 0.2% SDS to generate a chromatin fraction (C). The
primers used in this assay are shown in Table S2.
PMA-differentiated THP-1 cells or MDDCs, uninfected or infected with HIV/
Vpx for 6-8 hr, were fractionated into cytosolic (S1), membrane and organelle
(S2), and chromatin (P2) fractions (see the Supplemental Experimental Proce-
dures for detail).
In Vitro Interaction Assay
Recombinant GST-tagged wild-type and mutant PQBP1 proteins were
incubated with extra-chromosomal DNA isolated from MDDCs or PMA-THP
infected with HIV/Vpx using the Hirt extraction protocol (Arad, 1998). Three
hundred nanograms of GST or GST-PQBP1 protein was incubated with
100 ng of either extra-chromosomal DNA or a mixture of pNL43 HIV-1 provirus
plasmid and pUC19 in a binding buffer, followed by immunoprecipitation with
an antibody against either GST or PQBP1 (as indicated in each experiment).
DNA that associated with the recombinant proteins was analyzed by qPCR
using the HIV-1 30 LTR primer (Table S2).
Co-immunoprecipitation
HEK293T lysates expressingGFP or GFP fused towild-type, insertion C (delC),
or A194G substitution (WW) PQBP1 andwith V5-tagged cGASwere subjected
to immunoprecipitation analysis.
Immunostimulatory Assay
DNA that was isolated from the in vivo cross-linking interaction assay, either
from the cellular fractions or from the immunoprecipitants, were treated as
in in vivo interaction assay, above. DNA was electroporated into THP-1 using
the Neon transfection system (Life Technologies). Six to 8 hr post-electropora-
tion, RNA was isolated from the cells and subjected to qRT-PCR analysis.
In Vitro Assay for cGAMP Activity
The cGAMP activity assay was performed as described previously, with
some modifications (Wu et al., 2013; see the Supplemental Experimental
Procedures).
Ethics Statement
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